Trials / Completed
CompletedNCT04965870
A Study of Trifluridine/ Tipiracil in Chemorefractory mCRC in Greece
A Retrospective Observational Study of Trifluridine/ Tipiracil (TAS-102) in Chemorefractory Metastatic Colorectal Cancer (mCRC) in Greece. Real World Data on Clinical Benefit.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (actual)
- Sponsor
- Hellenic Study Group of Psychoneuroimmunology in Cancer · Network
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
Collection of real world data on the clinical efficacy of trifluridine/ tipiracil (FTD/TPI) in the Greek population.
Detailed description
The aim of this analysis is to record clinical practice and to collect real world data on the clinical efficacy of trifluridine/ tipiracil (FTD/TPI) in the Greek population. Main objectives include to assess physician's choice of treatment in chemoresistant metastatic colorectal cancer with FTD/TPI in third line and beyond In addition, the clinicopathologic features related to metastatic colorectal cancer (focus on molecular profile), duration of treatment, dose modification and toxicity will be analyzed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Trifluridine/Tipiracil | Trifluridine/ Tipiracil is an oral combination of an antineoplastic thymidine-based nucleoside analogue, trifluridine, and the thymidine phosphorylase (TPase) inhibitor, tipiracil hydrochloride. |
Timeline
- Start date
- 2021-06-30
- Primary completion
- 2021-10-31
- Completion
- 2021-12-20
- First posted
- 2021-07-16
- Last updated
- 2022-03-07
Locations
8 sites across 1 country: Greece
Source: ClinicalTrials.gov record NCT04965870. Inclusion in this directory is not an endorsement.